Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 404505, 14 pages
http://dx.doi.org/10.1155/2014/404505
Research Article

In Silico Investigation of Cytochrome P450 2C9 in relation to Aging Using Traditional Chinese Medicine

1Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
2School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan

Received 20 November 2013; Accepted 15 December 2013; Published 8 May 2014

Academic Editor: Fuu-Jen Tsai

Copyright © 2014 Tzu-Chieh Hung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Johnson, B. C. Lewis, D. J. Elliot, J. O. Miners, and L. L. Martin, “Electrochemical characterisation of the human cytochrome P450 CYP2C9,” Biochemical Pharmacology, vol. 69, no. 10, pp. 1533–1541, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Xiong, M. Wang, K. Fang et al., “A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China,” Genomics, vol. 97, no. 5, pp. 277–281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Surapureddi, R. Rana, and J. A. Goldstein, “NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes,” Pharmacological Research, vol. 63, no. 5, pp. 405–413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Yao, W.-W. Han, Y.-H. Zhou et al., “The inhibition effect of 20(S)-Protopanaxadiol (PPD) and Ginsenoside Rh2 for CYP2C9 and CYP3A4,” Polymer, vol. 48, no. 9, pp. 2644–2648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S.-F. Zhou, Z.-W. Zhou, and M. Huang, “Polymorphisms of human cytochrome P450 2C9 and the functional relevance,” Toxicology, vol. 278, no. 2, pp. 165–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Kimura, H. Ito, R. Ohnishi, and T. Hatano, “Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity,” Food and Chemical Toxicology, vol. 48, no. 1, pp. 429–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Zhai, A. Teumer, L. Stolk et al., “Eight common genetic variants associated with serum dheas levels suggest a key role in ageing mechanisms,” PLoS Genetics, vol. 7, no. 4, Article ID e1002025, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Waschatko, E. Kojro, M. Zahnow, and K. Gehrig-Burger, “Photo-DHEA—a functional photoreactive dehydroepiandrosterone (DHEA) analog,” Steroids, vol. 76, no. 5, pp. 502–507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Leowattana, “DHEAS as a new diagnostic tool,” Clinica Chimica Acta, vol. 341, no. 1-2, pp. 1–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Aldred and P. Mecocci, “Decreased dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer's disease (AD) patients,” Archives of Gerontology and Geriatrics, vol. 51, no. 1, pp. e16–e18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. E. Kihel, “Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)—recent reports,” Steroids, vol. 77, no. 1-2, pp. 10–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Panjari and S. R. Davis, “Vaginal DHEA to treat menopause related atrophy: a review of the evidence,” Maturitas, vol. 70, no. 1, pp. 22–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. K. de Souza, M. F. M. Ribeiro, and L. C. R. Kucharski, “Effects of dehydroepiandrosterone (DHEA) and lactate on glucose uptake in the central nervous system,” Neuroscience Letters, vol. 507, no. 1, pp. 62–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Wemm, T. Koone, E. R. Blough, S. Mewaldt, and M. Bardi, “The role of DHEA in relation to problem solving and academic performance,” Biological Psychology, vol. 85, no. 1, pp. 53–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Song, X. Tang, Y. Kong, H. Ma, and S. Zou, “The expression of serum steroid sex hormones and steroidogenic enzymes following intraperitoneal administration of dehydroepiandrosterone (DHEA) in male rats,” Steroids, vol. 75, no. 3, pp. 213–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Girardi, C. Luz, K. Cherubini, M. A. Z. D. Figueiredo, M. L. T. Nunes, and F. G. Salum, “Salivary cortisol and dehydroepiandrosterone (DHEA) levels, psychological factors in patients with oral lichen planus,” Archives of Oral Biology, vol. 56, no. 9, pp. 864–868, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Miao, J. Yang, C. Huang, and Z. Shen, “Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients,” European Journal of Clinical Pharmacology, vol. 63, no. 12, pp. 1135–1141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Kamali, T. I. Khan, B. P. King et al., “Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin,” Clinical Pharmacology and Therapeutics, vol. 75, no. 3, pp. 204–212, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. H.-J. Huang, H. W. Yu, C.-Y. Chen et al., “Current developments of computer-aided drug design,” Journal of the Taiwan Institute of Chemical Engineers, vol. 41, no. 6, pp. 623–635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Y. Chen, S. S. Chang, Y. C. Chan, and C. Y. Chen, “Discovery of novel insomnia leads from screening Traditional Chinese medicine database,” Journal of Biomolecular Structure & Dynamics, 2013. View at Google Scholar
  21. C. Y. Chen, “A novel integrated framework and improved methodology of computer-aided drug design,” Current Topics in Medicinal Chemistry, vol. 13, no. 9, pp. 965–988, 2013. View at Publisher · View at Google Scholar
  22. C. Y.-C. Chen, “TCM Database@Taiwan: the world's largest Traditional Chinese medicine database for drug screening In Silico,” PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Y.-C. Chen, “Computational screening and design of Traditional Chinese medicine (TCM) to block phosphodiesterase-5,” Journal of Molecular Graphics & Modelling, vol. 28, no. 3, pp. 261–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-C. Yang, S.-S. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Identification of potent EGFR inhibitors from TCM Database@Taiwan,” PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H.-J. Huang, K.-J. Lee, H. W. Yu et al., “Structure-based and ligand-based drug design for HER 2 receptor,” Journal of Biomolecular Structure & Dynamics, vol. 28, no. 1, pp. 23–37, 2010. View at Google Scholar · View at Scopus
  26. K.-C. Chen, M.-F. Sun, S.-C. Yang et al., “Investigation into potent inflammation inhibitors from Traditional Chinese Medicine,” Chemical Biology & Drug Design, vol. 78, no. 4, pp. 679–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K.-C. Chen and C. Yu-Chian Chen, “Stroke prevention by Traditional Chinese medicine? a genetic algorithm, support vector machine and molecular dynamics approach,” Soft Matter, vol. 7, no. 8, pp. 4001–4008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. K.-C. Chen, K.-W. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?” Molecular BioSystems, vol. 7, no. 9, pp. 2711–2719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. T.-T. Chang, M.-F. Sun, H.-Y. Chen et al., “Screening from the world's largest TCM database against H1N1 virus,” Journal of Biomolecular Structure & Dynamics, vol. 28, no. 5, pp. 773–786, 2011. View at Google Scholar · View at Scopus
  30. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “Two birds with one stone? Possible dual-targeting H1N1 inhibitors from Traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan,” Molecular BioSystems, vol. 7, no. 12, pp. 3366–3374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. T.-Y. Tsai, K.-W. Chang, and C. Y.-C. Chen, “IScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan,” Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. K.-W. Chang, T.-Y. Tsai, K.-C. Chen et al., “iSMART: an integrated cloud computing web server for Traditional Chinese medicine for online virtual screening, de novo evolution and drug design,” Journal of Biomolecular Structure & Dynamics, vol. 29, no. 1, pp. 243–250, 2011. View at Google Scholar · View at Scopus
  34. J. B. Schwartz, L. Kane, K. Moore, and A. H. B. Wu, “Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin,” Journal of the American Medical Directors Association, vol. 12, no. 9, pp. 633–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. P. S. Wells, H. Majeed, S. Kassem et al., “A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism,” Thrombosis Research, vol. 125, no. 6, pp. e259–e264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T.-L. Wang, H.-L. Li, W.-Y. Tjong et al., “Genetic factors contribute to patient-specific warfarin dose for Han Chinese,” Clinica Chimica Acta, vol. 396, no. 1-2, pp. 76–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. R. Wester, J. K. Yano, G. A. Schoch et al., “The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution,” The Journal of Biological Chemistry, vol. 279, no. 34, pp. 35630–35637, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. P. A. Williams, J. Cosme, A. Ward, H. C. Angove, D. M. Vinković, and H. Jhoti, “Crystal structure of human cytochrome P450 2C9 with bound warfarin,” Nature, vol. 424, no. 6947, pp. 464–468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. W. I. Tou and C. Y. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, 2013. View at Publisher · View at Google Scholar
  40. C. Y. C. Chen and W. L. Tou, “How to design a drug for the disordered proteins,” Drug Discovery Today, vol. 18, no. 19-20, pp. 910–915, 2013. View at Google Scholar
  41. C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, “LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites,” Journal of Molecular Graphics & Modelling, vol. 21, no. 4, pp. 289–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. B. R. Brooks, C. L. Brooks III, A. D. Mackerell Jr. et al., “CHARMM: the biomolecular simulation program,” Journal of Computational Chemistry, vol. 30, no. 10, pp. 1545–1614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. U. Velaparthi, P. Liu, B. Balasubramanian et al., “Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 11, pp. 3072–3076, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Rogers and A. J. Hopfinger, “Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships,” Journal of Chemical Information and Computer Sciences, vol. 34, no. 4, pp. 854–866, 1994. View at Google Scholar · View at Scopus
  45. Y. Fujikoshi, T. Noguchi, M. Ohtaki, and H. Yanagihara, “Corrected versions of cross-validation criteria for selecting multivariate regression and growth curve models,” Annals of the Institute of Statistical Mathematics, vol. 55, no. 3, pp. 537–553, 2003. View at Google Scholar · View at Scopus
  46. R.-E. Fan, P.-H. Chen, and C.-J. Lin, “Working set selection using second order information for training support vector machines,” Journal of Machine Learning Research, vol. 6, pp. 1889–1918, 2005. View at Google Scholar · View at Scopus
  47. H.-J. Böhm, “The computer program LUDI: a new method for the de novo design of enzyme inhibitors,” Journal of Computer-Aided Molecular Design, vol. 6, no. 1, pp. 61–78, 1992. View at Publisher · View at Google Scholar · View at Scopus
  48. J.-F. Wang and K.-C. Chou, “Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations,” Biochemical and Biophysical Research Communications, vol. 390, no. 3, pp. 608–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. K. C. Chen, S. S. Chang, H. J. Huang et al., “Three-in-one agonists for PPAR-alpha, PPAR-gamma, and PPAR-delta from Traditional Chinese medicine,” Journal of Biomolecular Structure & Dynamics, vol. 30, no. 6, pp. 662–683, 2012. View at Google Scholar
  50. Y.-R. Lin, H.-H. Chen, C.-H. Ko, and M.-H. Chan, “Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage,” European Journal of Pharmacology, vol. 537, no. 1–3, pp. 64–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. E.-J. Park, Y.-Z. Zhao, Y. H. Kim, B.-H. Lee, and D. H. Sohn, “Honokiol induces apoptosis via cytochrome c release and caspase activation in activated rat hepatic stellate cells in vitro,” Planta Medica, vol. 71, no. 1, pp. 82–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. G. C. Jagetia and T. K. Reddy, “Modulation of radiation-induced alteration in the antioxidant status of mice by naringin,” Life Sciences, vol. 77, no. 7, pp. 780–794, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. J.-M. Choi, B.-S. Yoon, S.-K. Lee, J.-K. Hwang, and R. Ryang, “Antioxidant properties of neohesperidin dihydrochalcone: inhibition of hypochlorous acid-induced DNA strand breakage, protein degradation, and cell death,” Biological and Pharmaceutical Bulletin, vol. 30, no. 2, pp. 324–330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. Y.-J. Jeong, Y.-J. Choi, J.-S. Choi et al., “Attenuation of monocyte adhesion and oxidised LDL uptake in luteolin-treated human endothelial cells exposed to oxidised LDL,” British Journal of Nutrition, vol. 97, no. 3, pp. 447–457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Lee, C.-H. Tsai, L. Wan et al., “Increased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central Taiwan,” BioMedicine, vol. 3, no. 2, pp. 92–94, 2013. View at Publisher · View at Google Scholar
  56. F.-J. Tsai, “Rare diseases: a mysterious puzzle,” BioMedicine, vol. 3, no. 2, p. 65, 2013. View at Publisher · View at Google Scholar
  57. C.-H. Wang, W.-D. Lin, and F.-J. Tsai, “Craniofacial dysmorphism, what is your diagnosis?” BioMedicine, vol. 2, no. 2, pp. 49–50, 2012. View at Publisher · View at Google Scholar
  58. Y.-T. Chang, W.-D. Lin, Z.-N. Chin et al., “Nonketotic hyperglycinemia: a case report and brief review,” BioMedicine, vol. 2, no. 2, pp. 80–82, 2012. View at Publisher · View at Google Scholar
  59. I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Möbius syndrome in a male with XX/XY mosaicism,” BioMedicine, vol. 3, no. 2, pp. 102–104, 2013. View at Publisher · View at Google Scholar
  60. I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Association analysis between Tourette's syndrome and two dopamine genes (DAT1, DBH) in Taiwanese children,” BioMedicine, vol. 3, no. 2, pp. 88–91, 2013. View at Publisher · View at Google Scholar
  61. W.-Y. Lin, H.-P. Liu, J.-S. Chang et al., “Genetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurysm formation,” BioMedicine, vol. 3, no. 2, pp. 73–81, 2013. View at Publisher · View at Google Scholar
  62. W.-L. Liao and F.-J. Tsai, “Personalized medicine: a paradigm shift in healthcare,” BioMedicine, vol. 3, no. 2, pp. 66–72, 2013. View at Publisher · View at Google Scholar
  63. F.-J. Tsai, “Biomedicine brings the future nearer,” BioMedicine, vol. 1, no. 1, p. 1, 2011. View at Publisher · View at Google Scholar